QIAGEN bags FDA nod for full GI testing on QIAstat-Dx Rise system
The approval means US laboratories can now run both respiratory and gastrointestinal panels on the high-throughput QIAstat-Dx Rise
The approval means US laboratories can now run both respiratory and gastrointestinal panels on the high-throughput QIAstat-Dx Rise
The new entity will operate with separate resources, funding, and operations, while BioNTech will contribute related rights and mRNA technologies to support its ambitious mission
Salanersen was generally well-tolerated, slowed neurodegeneration, and enabled functional gains
The move comes as the global biotech and biopharma CDMO market continues to surge, fueled by rising demand
The Phase 1 dose-escalation trial enrolled 25 evaluable patients and was designed to determine the recommended dose of LYMPHIR
Nearly 12 million people are estimated to be living with glaucoma, making the country one of the worst affected globally
The Hydrus Microstent stands out as the first and only MIGS device backed by five-year clinical outcomes
The new equipment will be installed at Codis’ 400,000-square-foot Haverhill facility and is expected to be operational by 2027
The first of four planned modules at the new plant is expected to come online by summer 2026
Subscribe To Our Newsletter & Stay Updated